Adverse Events Associated With Long-term Treatment of Epithelial Ovarian Cancer With Bevacizumab and Chemotherapy

Yokoyama, Yuka; Kubo-Kaneda, Michiko; SUNADA, KIMI; Teishikata, Yasuhiro; Kitamura, Asa; Okamoto, Kousuke; Toriyabe, Kuniaki; Nii, Masafumi; Yoshida, Kenta; Kondo, Eiji; Ikeda, Tomoaki

doi:10.21873/anticanres.15916

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding ≥ grade 3 adverse events for all recurrent settings, the profile and incidence rate did not appear to exhibit the large differences reported in OCEANS and AURELIA, as far as the available data in those trials were concerned. Also, previous real-world data studies on Japanese patients showed comparable data on adverse events (28,29). There were no severe adverse events that directly led to mortality in the present study.…”

Section: Discussionsupporting

confidence: 82%

Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Müllerian Cancer: A Single-institutional Experience

et al. 2023

View full text Add to dashboard Cite

Background/Aim: The efficacy and safety of bevacizumab for ovarian cancer have been reported in randomized phase III clinical trials. It is important to gather experience and data in a real-world setting. The objective of the present study was to evaluate the efficacy and safety of bevacizumab for patients with ovarian cancer in a real-world setting. Patients and Methods: For front-line settings, patients with FIGO stage III-IV ovarian cancer treated using bevacizumab and chemotherapy after debulking surgery (Chemo + Bev group, n=79), in addition to those treated with only chemotherapy after debulking surgery (Chemo group; n=66), at our institute were reviewed retrospectively. For recurrent settings, patients with recurrent ovarian cancers treated with bevacizumab and any chemotherapy were reviewed retrospectively (n=65). Results: In the front-line setting, the disease-free survival was significantly longer in the Chemo + Bev group compared with that in the Chemo group (p=0.021). Hypertension and proteinuria were found to be statistically more frequent in the Chemo + Bev group compared with that in the Chemo group (p=0.002 and p=0.004). In the recurrent setting, in platinum-sensitive patients, the response rate (RR) and the disease control ratio (DCR) were 78.4 and 94.1%, respectively. In platinum-resistant patients, the RR and the DCR were 28.6 and 57.1% respectively. The median progression-free survival was 18.3 and 7.1 months for platinum-sensitive recurrence and platinum-resistant recurrence, respectively. The major ≥ grade 3 adverse event was neutropenia. Conclusion: The present study provided encouraging real-world evidence of the efficacy and safety of bevacizumab for ovarian cancer in real-world.

show abstract

Section: Discussionsupporting

confidence: 82%

Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Müllerian Cancer: A Single-institutional Experience

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The first is the most abundant showing MW of about 23.8 kDa, a pI of 9.5 and a pH optimum around neutrality (33). Bromelain from the fruit on the contrary has a slightly higher MW (25 kDa), a more acidic pI (4.6) and a broader pH optimum (3)(4)(5)(6)(7)(8). All these differences on the whole may be, at least in part, responsible for the very different results observed in all the clinical and preclinical studies (33,35).…”

Section: Physicochemical Characteristicsmentioning

confidence: 99%

“…Chemotherapy is a systemic treatment, administered to destroy tumor cells or stop their multiplication ( 3 ). The cytotoxic action also manifests itself in healthy cells that multiply rapidly (eg hair, and cells of the intestinal mucosa), causing adverse reactions ( 4 ). Chemotherapy is administered strictly according to the type of tumor cell and the patient’s response to treatment ( 5 , 6 ).…”

Section: Introductionmentioning

confidence: 99%

Anticancer properties of bromelain: State-of-the-art and recent trends

Pezzani

Jiménez-Garcia²,

Capó³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Bromelain is a key enzyme found in pineapple (Ananas comosus (L.) Merr.); a proteolytic substance with multiple beneficial effects for human health such as anti-inflammatory, immunomodulatory, antioxidant and anticarcinogenic, traditionally used in many countries for its potential therapeutic value. The aim of this updated and comprehensive review focuses on the potential anticancer benefits of bromelain, analyzing the cytotoxic, apoptotic, necrotic, autophagic, immunomodulating, and anti-inflammatory effects in cancer cells and animal models. Detailed information about Bromelain and its anticancer effects at the cellular, molecular and signaling levels were collected from online databases such as PubMed/MedLine, TRIP database, GeenMedical, Scopus, Web of Science and Google Scholar. The results of the analyzed studies showed that Bromelain possesses corroborated pharmacological activities, such as anticancer, anti-edema, anti-inflammatory, anti-microbial, anti-coagulant, anti-osteoarthritis, anti-trauma pain, anti-diarrhea, wound repair. Nonetheless, bromelain clinical studies are scarce and still more research is needed to validate the scientific value of this enzyme in human cancer diseases.

show abstract

“…In particular, anti-angiogenic agents targeting the vascular endothelial growth factor (VEGF) pathway have demonstrated clinical efficacy in the treatment of several cancers (1-3). Among the various side effects (SEs) of VEGF receptor (VEGFR)-targeted agents, proteinuria is relatively common (4), particularly in patients with metastatic colorectal cancer (mCRC) and metastatic renal cell carcinoma (mRCC), and its pathogenesis is multifocal (5)(6)(7). Proteinuria due to the use of anti-angiogenic agents may decrease renal function or cause nephrotic syndrome in patients (8).…”

mentioning

confidence: 99%

Efficacy and Safety of Anti-angiogenic Agents for Cancer Patients With Proteinuria or a History of Proteinuria: A Systematic Review

KATO,

KURASAWA,

TAKEZAWA

et al. 2024

Anticancer Res

View full text Add to dashboard Cite

Background/Aim: The safety and efficacy of antiangiogenic agents in patients with cancer with proteinuria and a history of proteinuria are not well established. This systematic review aimed to answer these questions. Materials and Methods: We searched three electronic databases for articles published until June 18, 2021. The main outcomes used were "death", "renal impairment", and "proteinuria impairment". Results: After screening 303 references in the PubMed, Cochrane Library, and ICHUSHI-web databases, this review included five studies on renal cell carcinoma (RCC). In patients with metastatic RCC, the hazard ratio of the presence of (or having) proteinuria (1+ or higher) at baseline was 0.82 (0.23-2.97); thus, proteinuria was not significantly associated with the outcome of death. No significant deterioration in kidney function was observed in patients with proteinuria. Although proteinuria at baseline was a significant risk factor for proteinuria progression during and after treatment, most patients maintained grade 1 or 2 proteinuria and continued treatment without dose reduction or discontinuation. Conclusion: While weak evidence suggests that proteinuria at the start of treatment with anti-angiogenic agents might be a risk factor for worsening proteinuria, it was not significantly associated with death or renal impairment.

show abstract

Adverse Events Associated With Long-term Treatment of Epithelial Ovarian Cancer With Bevacizumab and Chemotherapy

Cited by 5 publications

References 0 publications

Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Müllerian Cancer: A Single-institutional Experience

Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Müllerian Cancer: A Single-institutional Experience

Anticancer properties of bromelain: State-of-the-art and recent trends

Efficacy and Safety of Anti-angiogenic Agents for Cancer Patients With Proteinuria or a History of Proteinuria: A Systematic Review

Contact Info

Product

Resources

About